Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

JC-Virus (JCV) Antibody Program (STRATIFY-1)

This study has been completed.
Sponsor:
Collaborators:
United BioSource Corporation
Elan Pharmaceuticals
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT01070823
First received: February 17, 2010
Last updated: October 4, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2012
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)